CANNDOC Pharma

Company Overview

Snapshot

Founded in January 2008, CANNDOC Pharma operates with 1–10 employees. The company was acquired by InterCure in September 2018, marking a significant milestone in its trajectory within the medical cannabis sector.

Business overview

CANNDOC Pharma develops pharma-grade cannabis products, serving the Health Tech & Life Sciences sector. The company's core technology focuses on medical cannabis, with expertise spanning research, cultivation, processing, and product development. CANNDOC Pharma's GMP-standard products are prescribed for various indications, including neuropathic pain, cancer-related pain, inflammatory bowel disease, PTSD, Parkinson's disease, and epileptic seizures. The company operates in the medical cannabis market, adhering to European, Canadian, and Israeli regulatory requirements.

Strategic signal

In January 2024, InterCure, CANNDOC Pharma's parent company, signed a definitive agreement to acquire Leon Pharm Ltd., an Israeli pharmacy chain specializing in medical cannabis. This strategic acquisition is poised to expand InterCure's distribution network and strengthen its market position in response to new medical cannabis reforms by the Israeli Ministry of Health. This signals a continued aggressive expansion strategy and market consolidation within the Israeli medical cannabis industry, indicating growth opportunities for CANNDOC Pharma's product distribution.

Company Intelligence Q&A

What was a significant acquisition involving CANNDOC Pharma's parent company in 2024?

In January 2024, InterCure, CANNDOC Pharma's parent company, signed a definitive agreement to acquire Leon Pharm Ltd., an Israeli pharmacy chain specializing in medical cannabis. This acquisition is expected to enhance InterCure's distribution network and market position.

When was CANNDOC Pharma acquired and by whom?

CANNDOC Pharma was acquired by InterCure in September 2018. This acquisition significantly boosted InterCure's share price and positioned CANNDOC Pharma within a larger corporate structure.

What strategic partnership did CANNDOC Pharma's parent company form in December 2020?

In December 2020, InterCure, the owner of CANNDOC Pharma, formed a strategic alliance with Charlotte's Web, a leader in hemp CBD extract products. This agreement facilitated the exclusive distribution of Charlotte's Web hemp extract wellness products in Israel through CANNDOC Ltd., with potential future expansion into European markets.

What was the nature of the partnership between CANNDOC Pharma and Super-Pharm in March 2020?

In March 2020, CANNDOC Pharma entered into a strategic partnership agreement with Super-Pharm, Israel's largest drugstore chain. Under this agreement, Super-Pharm committed to acquiring 10 tons of CANNDOC's GMP medical cannabis products over three years for distribution to its medical cannabis authorized pharmacies.

What significant international cooperation deal did InterCure's subsidiary CANNDOC sign in January 2020?

In January 2020, InterCure's subsidiary CANNDOC signed a cooperation agreement with Tilray. This deal allowed CANNDOC to import 2.5 tons of Tilray's cannabis products for the Israeli market and export five tons of cannabis to Tilray for marketing under the Tilray brand, pending export approvals from Israel.